Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin

Inclusion Criteria

• •1. Histologic or cytologic diagnosis of pancreatic cancer or cholangiocarcinoma
• •2. Liver predominant disease defined as
• •\- Cholangiocarcinoma: liver disease should be unresectable
• •\- Limited extra hepatic metastasis defined as: i. Lung metastasis: 6 or less nodules with no nodule greater than 1.5 cm.
• •ii. Abdominal lymph nodes iii. Pancreatic primary as long as the size is less than 4 cm in size iv. Bone metastasis
• •3. No prior systemic therapy for advanced stage disease
• •4. Measurable target tumors using standard imaging techniques
• •5. Lung shunting less than 20%
• •6. ECOG performance status 0-1 (See Appendix )
• •7. Age ≥ 18 years
• •8. No other investigational agents while on protocol
• •9. Signed informed consent